Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. by Cunnama, Lucy et al.
Cunnama, L; Sinanovic, E; Ramma, L; Foster, N; Berrie, L; Stevens,
W; Molapo, S; Marokane, P; McCarthy, K; Churchyard, G; Vas-
sall, A (2016) Using Top-down and Bottom-up Costing Approaches
in LMICs: The Case for Using Both to Assess the Incremental Costs
of New Technologies at Scale. Health economics, 25 Suppl 1. pp.
53-66. ISSN 1057-9230 DOI: 10.1002/hec.3295
Downloaded from: http://researchonline.lshtm.ac.uk/2528162/
DOI: 10.1002/hec.3295
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons: Attribution-No Derivative Works 3.0
http://creativecommons.org/licenses/by-nd/2.5/
USING TOP-DOWN AND BOTTOM-UP COSTING APPROACHES IN
LMICS: THE CASE FOR USING BOTH TO ASSESS THE INCREMENTAL
COSTS OF NEW TECHNOLOGIES AT SCALE
LUCY CUNNAMAa,*, EDINA SINANOVICa, LEBOGANG RAMMAa, NICOLA FOSTERa, LEIGH BERRIEb,
WENDY STEVENSb, SEBAKA MOLAPOb, PULENG MAROKANEb, KERRIGAN MCCARTHYc,
GAVIN CHURCHYARDc,d,e and ANNA VASSALLe
aHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
bNational Priority Programmes, National Health Laboratory Services, Johannesburg, South Africa
cAurum Institute for Health Research, Johannesburg, South Africa
dSchool of Public Health, University of Witwatersrand, Johannesburg, South Africa
eLondon School of Hygiene and Tropical Medicine, London, United Kingdom
ABSTRACT
Purpose – Estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is
a methodologically challenging and substantial empirical undertaking, in the absence of routine cost data collection. We
demonstrate a best practice pragmatic approach to estimate the incremental costs of new technologies in low-income and
middle-income countries, using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance
to riframpicin (RIF) in South Africa.
Materials and methods – We estimate costs, by applying two distinct approaches of bottom-up and top-down costing,
together with an assessment of processes and capacity.
Results – The unit costs measured using the different methods of bottom-up and top-down costing, respectively, are
$US16.9 and $US33.5 for Xpert MTB/RIF, and $US6.3 and $US8.5 for microscopy. The incremental cost of Xpert
MTB/RIF is estimated to be between $US14.7 and $US17.7. While the average cost of Xpert MTB/RIF was higher than
previous studies using standard methods, the incremental cost of Xpert MTB/RIF was found to be lower.
Conclusion – Costs estimates are highly dependent on the method used, so an approach, which clearly identiﬁes resource-
use data collected from a bottom-up or top-down perspective, together with capacity measurement, is recommended as a
pragmatic approach to capture true incremental cost where routine cost data are scarce.
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1. INTRODUCTION
In many low-income and middle-income countries (LMICs), health system capacity is severely constrained,
and the roll-out of new technologies for common diseases often occurs at a rapid pace and large scale, often
without demonstration of the cost of scale-up. Initial assessments of the costs and cost-effectiveness of new
technology scale-up are often based on costs collected from small-scale demonstrations or trial settings. How-
ever, costs at scale and in routine settings may substantially differ. This difference is likely to operate in several
directions: on the one hand, in routine settings, procedures and staff may perform less well or efﬁciently than in
small-scale trial sites; on the other hand, there may be economies of scale from roll-out. In addition, trial-based
costing is often unable to assess the extent to which the existing capacity of ﬁxed (health system) resources can
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sufﬁciently absorb any new technology at scale. Therefore, there may be considerable uncertainty around estimates
of true system-wide incremental cost. These factors have led some authors to conclude that key policy decisions
should not be based on the results of costing studies that do not include an assessment of current capacity utilisation
(Adam et al., 2008). Finally, early trial-based estimates often exclude any incremental above delivery site-level/
laboratory-level costs; for instance, the human resource management, supply chain management and information
technology support required to support rapid scale-up.
While in high-income countries, estimating costs at scale may be a matter of extraction from routine systems
(Chapko et al., 2009); in many LMICs, routine reporting of procedure-speciﬁc/service-speciﬁc costs is scarce
(Conteh and Walker, 2004). In practice, many health economists working in LMICs spend large proportions of
their effort and time collecting empirical cost data as part of any economic evaluation of new technologies when
ﬁrst rolled-out. This empirical effort is considered essential, both in terms of arriving at accurate incremental cost-
effectiveness ratios and assisting programme managers and funders in planning and budgeting for scale-up, but
these large studies can be both resource intensive and costly. Given the limited resources and capacity in economic
evaluation in LMICs, developing efﬁcient cost methods is an important methodological ﬁeld of enquiry.
A key decision in costing, which fundamentally impacts study cost and resource requirements, is whether to use
a top-down or bottom-up approach. In simple terms, in a top-down approach, the analyst takes overall expenditures
for each ingredient/input at a central level and then allocates costs using formulae (based on allocation factors such
as building usage, staff time and staff numbers) to estimate unit procedure or service costs (Flessa et al., 2011;
Conteh and Walker, 2004). A bottom-up approach uses detailed activity and input usage data from records
(or observed usage) at the service provider level to estimate unit costs (Chapko et al., 2009; Batura et al., 2014).
Previous research, for example, Hendriks et al. (2014), mostly suggests that when bottom-up and top-down
methods are compared, bottom-up costing is likely to be more accurate, as it is assumed to capture more
comprehensively the resources used in providing a particular service. It is also suggested by others that the data
required for bottom-up costing may be easier to access than that for top-down costing. However, bottom-up
costing may be considered more time demanding, speciﬁc to the setting and expensive to undertake (Wordsworth
et al., 2005; Simoens, 2009). Another study comparing the two methods, based on national data in the United
States of America (Chapko et al., 2009), searched for agreement between bottom-up and top-down methods
and highlighted the strength of each method for assessing different constructs of costs: top-down methods capture
national long run average costs, while bottom-up methods capture site-level differences.
In practice, however, because of limited data availability in LMICs, most researchers costing at the site level use a
mixture of bottom-up and top-down methodologies (Hendriks et al., 2014) depending on the importance and data
availability for each ingredient in the costing. This mixed approach is also conventionally applied to obtain the incre-
mental cost estimates used in economic evaluations (Wordsworth et al., 2005). For example, staff costs and somema-
terial costs may be estimated using a bottom-up approach, whereas equipment costs, consumables and building space
are assessed using a top-down methodology (Hendriks et al., 2014). There is a plethora of disease-speciﬁc costing
tools currently available to guide researchers collecting costs in LMICs with a detailed list of ingredients and some
collection of overhead costs (or a mark-up) at the service level (UNAIDS, 2011; World Health Organization, 2002).
We argue here that, as commonly applied in LMICs, bottom-up and top-down methods capture fundamen-
tally different types of cost; and therefore, more care has to be taken when mixing these methods, or assuming
one method is more accurate compared with another. This is particularly the case when applying these costs to
the estimation of incremental cost for the purposes of economic evaluation. Our central thesis is that bottom-up
costing methods, although accurate in capturing a comprehensive minimum cost, may under-report inefﬁciency
or under-utilised capacity, whereas top-down methods fully capture this inefﬁciency, although they may be less
‘accurate’ than bottom-up costing. By reﬂecting different extents of inefﬁciency and under-utilised capacity, a
mixed approach may misrepresent true incremental costs of new technologies implemented at scale.
To illustrate this argument, we use the example of the introduction of a new diagnostic for tuberculosis (TB), the
Xpert test which identiﬁes Mycobacterium tuberculosis (MTB) Deoxyribonucleic acid (DNA) and resistance to
riframpicin (RIF) (Cepheid, Sunnyvale, California) in South Africa. We compare the use of the top-down and
bottom-up costing methods to answer the following questions: How do total costs of TB diagnosis change over time
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during Xpert MTB/RIF scale-up?; andWhat are the unit and incremental costs of performing Xpert MTB/RIF under
routine conditions during scale-up?We also examine a range of other indicators of capacity usage and combine these
with both sets of cost estimates to provide an indication of incremental cost, and in doing so, demonstrate a pragmatic
method for improving the evaluation of costs of new technologies at scale in LMIC settings.
2. STUDY DESIGN, MATERIALS AND METHODS
2.1. Background
Tuberculosis control is an important global health concern. In 2012, the estimated number of individuals who devel-
oped active TB worldwide was 8.6 million, of which 13% were co-infected with the human immunodeﬁciency virus
(HIV). South Africa is a high TB incidence setting with around 860 cases per 100 000 population (World Health
Organization, 2014). South Africa notiﬁes the highest number of extensively drug-resistant TB cases in the world. His-
torically, the diagnosis of TB has been conducted using smear microscopy (hereafter written as microscopy). Micros-
copy has a limited sensitivity and cannot identify multi-drug resistant tuberculosis (MDR-TB). In recent years,
considerable effort and funding have gone into developing rapid diagnostic tests for TB that include the identiﬁcation
of MDR-TB and that are affordable and feasible for use in LMICs. The Xpert MTB/RIF assay is an automated
cartridge-based molecular test that uses a sputum specimen to detect TB as well as rifampicin resistance. Results pub-
lished in a recent Cochrane Systematic Review found that Xpert MTB/RIF has a speciﬁcity of 99% and a sensitivity of
89%, compared with a 65% sensitivity in microscopy. Xpert MTB/RIF is also both sensitive and speciﬁc in detecting
pulmonary TB in those with HIV infection (Steingart et al., 2014). In 2010, the World Health Organisation (WHO)
made the recommendation that XpertMTB/RIF replacemicroscopywhere resources permit this change (WHO, 2013).
Model-based economic evaluations by Vassall et al. (2011a, 2011b) and Menzies et al. (2012a, 2012b),
which followed shortly after this recommendation, suggested that the introduction of Xpert MTB/RIF is
cost-effective and could lead to a considerable reduction in both TB morbidity and mortality in Southern
Africa. However, the concern was raised that Xpert MTB/RIF may place increased demand on scarce
healthcare resources (Menzies et al., 2012a) and has a high opportunity cost. These early analyses used a mixed
but primarily bottom-up costing method, which was rapid and based either on product prices or on retrospective
trial cost data collection at a small number of demonstration trial sites.
2.2. Xpert for TB: Evaluating a New Diagnostic (XTEND) study setting and site selection
Following the WHO (2010) recommendation, a substantial investment was made to rapidly roll-out Xpert
MTB/RIF in South Africa. The intention was for Xpert MTB/RIF to be rolled out nationally using a staged
approach over 2 years, starting in 2011 (Vassall et al., 2011a; Vassall et al., 2011b). After a request by the National
Department of Health, the roll-out was initiated with the introduction of 30 Xpert MTB/RIF instruments placed in
laboratories with a priority for high-burden TB areas (National Health Laboratory Service, 2013).
As part of the South African roll-out, the Department of Health agreed to a pragmatic trial, XTEND (of which
this work is a part), funded by the Bill and Melinda Gates Foundation, to evaluate both the impact and cost-
effectiveness of Xpert MTB/RIF introduction in routine settings. Ethical approval for the XTEND study was
granted by the ethics committees of the University of Witwatersrand, the University of Cape Town, the London
School of Hygiene and Tropical Medicine and WHO. The study ran from 2011 until the end of 2013. The
XTEND study was a pragmatic cluster randomised study that evaluated the mortality impact and cost-
effectiveness of Xpert MTB/RIF roll-out in South Africa (Churchyard, 2014). The trial was implemented in four
provinces, namely, the Eastern Cape, Mpumalanga, Free State and Gauteng (Table I). The Western Cape,
Limpopo, North West, KwaZulu Natal and the Northern Cape provinces were not included in the XTEND study.
In order to reﬂect a mix of implementation and geographical settings, a range of laboratories were included.
We selected all 20 XTEND peripheral laboratories and one reference laboratory to explore how costs vary with
scale as comprehensively as was feasible. The 20 peripheral laboratories were stratiﬁed by province. They were
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then randomised (see Churchyard et al., 2015 for more information) by a statistician using STATA (version 11,
StataCorp LP, College Station, Texas, USA) to the intervention arm, where Xpert MTB/RIF was implemented
immediately, or the control arm, where Xpert MTB/RIF implementation was delayed and laboratories continued
to use microscopy until implementation (Churchyard et al., 2015). In order to capture cost at different scales of
Xpert MTB/RIF implementation, we measured costs at several time points (Figure S2). Firstly, intervention
laboratories were costed at start-up during observation 1 (July and October 2012) (early stage of Xpert
MTB/RIF implementation) and approximately 6 months after Xpert MTB/RIF introduction during observation
2 (late stage of Xpert MTB/RIF implementation) at the beginning of 2013 (March 2013). At the control laborato-
ries, microscopy was also costed at the beginning of the trial (August 2012). In addition, at the end of the trial
period (post-enrolment), the control laboratories began to implement Xpert MTB/RIF. This did not impact the trial
because the intervention occurred at enrolment but gave the opportunity to cost Xpert MTB/RIF as it was being
introduced at very low levels of usage (February and June 2013) (start-up of Xpert MTB/RIF implementation).
2.3. Tuberculosis tests costed
Microscopy and Xpert MTB/RIF were costed in all control and intervention laboratories. At the reference labora-
tory, we costed microscopy, TB culture, drug-sensitivity testing (DST) and polymerase chain reaction tests (see
Supporting Information and Figure S3 for more information about tests and the current diagnostic algorithm).
TB culture was conducted using a Mycobacteria Growth Indicator Tube (MGIT) (BD Microbiology Systems,
Cockeysville, MD, USA). The polymerase chain reaction test assessed was theMTBDRplus test (Hain Lifescience,
Nehren, Germany), a line probe molecular assay. DST is conducted to identify which speciﬁc TB drugs the TB
strain is resistant to and also makes use of a MGIT tube and MGIT system (National Department of Health, 2014).
Table I. Site description of 21 laboratories observed
Laboratory
study arm
and number Province
Annual number of
microscopy tests (for
ﬁnancial year 2012/2013)
Annual number of Xpert
MTB/RIF tests (for ﬁnancial
year 2012/2013)
Number of
observing visits
for microscopy
Number of
observing visits
for Xpert MTB/
RIF
Intervention
Lab 1 Free State 8014 15 892 2 2
Lab 2 Gauteng 30 031 15 257 2 2
Lab 3 Gauteng 12 655 15 378 2 2
Lab 4 Mpumalanga 19 105 9950 1 1
Lab 5 Eastern Cape 5376 12 410 2 2
Lab 6 Eastern Cape 12 676 12 739 2 2
Lab 7 Eastern Cape 14 940 8406 2 2
Lab 8 Gauteng 20 644 12 471 1 1
Lab 9 Gauteng 0 1212 0 1
Lab 10 Eastern Cape 5713 11 747 0 1
Control
Lab 11 Gauteng 27 401 774 1 1
Lab 12 Mpumalanga 63 328 1088 2 1
Lab 13 Free State 29 427 211 2 1
Lab 14 Gauteng 25 602 375 1 1
Lab 15 Eastern Cape 32 700 0 2 0
Lab 16 Eastern Cape 52 565 0 2 0
Lab 17 Eastern Cape 25 526 2425 2 1
Lab 18 Gauteng 26 465 23 1 0
Lab 19 Eastern Cape 15 710 2 1 0
Lab 20 Gauteng 2665 5 0 0
Reference laboratory
Lab 21 Gauteng 73 115 0 1 0
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2.4. Costing methodology
We estimated costs using both a top-down approach and a bottom-up approach, with a complementary process
assessment (Supporting Information). Our bottom-up method primarily used detailed records and observation
to measure resource use. For example, the cost of an Xpert MTB/RIF machine is estimated according to the
number of minutes it was observed to be used (for each test) multiplied by the cost per minute. Other methods
for bottom-up costing included using patient or provider semi-structured interviews to determine resource use,
particularly how long a service takes to deliver (Supporting Information).
We conducted our top-down costing by allocating total laboratory expenditures between site-level activities
and tests, using measured or recorded allocation criteria. For example, the cost of a laboratory staff member
may be allocated between several tests, based on their time usage recorded through timesheets. This allocated
cost was then divided by the conducted number of tests. Timesheets were primarily used for top-down cost
allocation, whereas observation of time spent on processing was used for bottom-up costing.
2.5. Measurement and valuation methods for site-level costs
The overarching approach was micro-costing rather than gross-costing. All recurrent and capital costs involved
in TB diagnosis were ﬁrst identiﬁed for all the laboratories, using interviews and observations of processes.
Recurrent inputs identiﬁed included human resource costs, overheads and running costs (utilities, etc.),
chemicals and consumables. Capital costs included building, equipment and furniture costs. A data collection
and management tool was developed in Microsoft Excel (Redmond, WA, USA), in order to allow for system-
atic gathering of information. This tool was tested in three pilot laboratories in the Western Cape prior to com-
mencing data collection, which aided the understanding of practices in laboratories, allowed for modiﬁcation of
the tool and prepared the researchers for ﬁeldwork.
Bottom-up unit costs were then estimated through the observation of TB testing in the laboratories. A mixed
method approach was utilised, incorporating timed observation of staff procedures and discussion with labora-
tory staff and managers to better understand processes and procedures, how observed resource usage is related
to routine practice, assessment of workload (including batching) and other key diagnostic processes. Sputum
specimens were observed from delivery to recording of test results. Staff members were observed, their level
of qualiﬁcation was noted and the hands-on processing was timed for each component of the testing. Two to
four batches were observed for each test (each microscopy batch had an average of 29 specimens, and each
Xpert MTB/RIF batch had an average of 15 specimens), depending on the size of the batches and limits of
the observation period. Equipment usage was documented, as was the quantity of consumables, chemicals
and reagents utilised. The processing area (ﬂoor and desk spaces) was measured for each component of the test-
ing. Management and space-related overheads were allocated using mark-ups, respectively, on the basis of a
‘per minute’ and ‘per metre’ usage using overall laboratory expenditures, stafﬁng hours and space.
For the top-down costs, total costs for the entire laboratory were ﬁrst determined using ﬁnancial records on the
total expenditure and ﬁxed assets of the laboratory (for overheads, transport, and personnel and building spaces),
and total expenditures were used for the TB section for chemicals and reagents, consumables and equipment.
Valuation of equipment, other capital items and building space used replacement prices. Allocation of total labo-
ratory expenditure to the TB section depended on the input (overheads, transport, equipment, etc.). The proportion
of space used for TB diagnostics was measured and used for allocation of general building, utilities, cleaning and
security costs. Timesheets were used for management and administration costs and were ﬁlled for the duration of
1 week. Transport costs (for the collection of specimens from the clinics) were allocated using the annual number
of TB tests performed at the laboratory as a percentage of the total number of all tests processed in the laboratory.
Allocation of all costs to speciﬁc TB tests was carried out through staff involved in TB procedures ﬁlling in
timesheets for the period of 1 week themselves. After this period, interviews were held with the researchers, in
order to apportion time usage and complete the timesheets. Building space was allocated according to proportional
use (combining space measured and proportional time per test), and test speciﬁc consumables and reagents costs
were sourced through scrutiny of ﬁnancial and laboratory records.
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2.6. Measurement and valuation methods for above site-level costs
In order to capture the broader ‘above laboratory’ costs, expenditures for the above laboratory services such as
human resource management, information technology and ﬁnance departments were obtained from the National
Health Laboratory Service (NHLS). Following interviews with NHLS and detailed discussions with management
staff, management costs were divided by the national laboratory staff numbers for NHLS and then allocated to the
speciﬁc laboratories based on the number of employees in the laboratory as a proxy for laboratory size. These costs
were then allocated to speciﬁc tests using the number of tests performed and weighted by time observed for each
test. These were then used for bottom-up and top-down costing.
The NHLS provided detailed costs for transport of specimens, calibration of instruments, personnel and training
and other above laboratory costs for the laboratories. In addition, the NHLS provided data on key prices, such as
replacement costs for buildings and equipment and prices of reagents and consumables. Cepheid provided prices
for the Xpert MTB/RIF equipment, test kits and calibration. The prices of other items were obtained directly from
medical suppliers and companies in the industry, such as Lasec, Sigma and The Scientiﬁc Group. These prices are
all related to the study year 2013. All capital items were annuitised using a 3% discount rate, where buildings were
expected to have a life expectancy of 30 years and equipment and furniture 2–15 years.
2.7. Data analysis
Total costs were estimated for each site. Average and median costs per test using both bottom-up and top-down
methods were calculated and compared over time and between control and intervention groups. We also estimated
the average incremental cost of Xpert MTB/RIF using two methods. The ﬁrst was a simple comparison between
the average (unit) cost of a diagnostic specimen in the control and intervention sites costs. However, as the division
of sites, between control and intervention sites, was not balanced for efﬁciency, we adopted an additional method.
This second method is a comparison of the total cost of both Xpert MTB/RIF and microscopy diagnosis in the
intervention sites with the total cost of the same number of tests but assuming they were conducted using
microscopy testing. Both methods use the top-down unit costs described earlier.
Given the small sample size, and thus exploratory nature of results, in order to explore economies of scale, we
used an ordinary least squares regression analysis of the number of Xpert MTB/RIF tests processed in the year
(dependent variable) versus the unit costs (independent variable) (top-down and then bottom-up measured during
the ﬁrst and second observations). We did not statistically analyse any other drivers of costs (again given the small
sample size). We use the results of our process analysis to interpret and arrive at conclusions on both the incremen-
tal costs and laboratory systems implications of the scale-up of Xpert MTB/RIF. Results are presented in US
dollars ($US1=ZAR9.62) (www.oanda.com average exchange rate from January–December 2013).
3. RESULTS
3.1. Sites costed
Our ﬁnal sample, number of tests performed per laboratory and number of observations made, is depicted in
Table I. As is common in costing studies in ‘real-world’ LMIC settings during scale-up, in practice, it was
not feasible to observe all the laboratories during both periods for various reasons (Tables SI and SII). Firstly,
it was not possible to observe microscopy in the ﬁrst observation of the intervention sites for two sites because
processing of microscopy specimens was not being performed at the time (lab 9 had stopped processing micros-
copy specimens because of downscaling, and lab 10 had shortages of staff and so was not processing microscopy
during the time of observation). In the second observation, it was not feasible to observe Xpert MTB/RIF testing in
all sites because of a number of reasons: closing of laboratories due to downscaling; changing of laboratory infor-
mation system and auditing of laboratory (both of which meant that researchers were unable to be in the laboratory
over this period); tests not being processed due to lack of stock or lack of staff; and night-time processing in inac-
cessible areas. Of the intended 70 observations for microscopy and Xpert MTB/RIF, 49 were undertaken (70%).
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3.2. Total costs
Figure 1a presents the trend of total costs for the intervention laboratories using the top-down approach (averaged
for the two observations) for both microscopy and Xpert MTB/RIF, respectively, over 1 year. The corresponding
number of tests processed can be seen in Figure 1b. The overall cost of Xpert MTB/RIF broadly increases over
time with the phased implementation of Xpert MTB/RIF in intervention laboratories. In intervention laboratories,
the costs of microscopy do not fall to zero as microscopy tests are used to monitor response to treatment. Xpert
MTB/RIF has an estimated annual total cost of $US2 805 727 across the 10 intervention sites (Figure 1a). Figure S1
presents the corresponding total costs in the control sites, which have higher annual microscopy costs
($US1 992 434) than the intervention sites.
Figure 1. (a) Total costs for Xpert MTB/RIF and microscopy for 10 intervention laboratories for the ﬁnancial year 2012/2013 ($US2013).
(b) Figures for Xpert MTB/RIF and microscopy tests processed for 10 intervention laboratories for the ﬁnancial year 2012/2013
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The breakdown of total costs for Xpert MTB/RIF by input during each observation is presented in Table SIII.
In the intervention laboratories, the proportion of total costs attributed to reagents and chemicals was on average
62% for observation 1 and 64% for observation 2. In the control laboratories, the cost for reagents and chemicals
was only 24% in observation 2 (post-Xpert MTB/RIF implementation) on average. Labour costs during the ﬁrst
and second observations accounted for 8% and 7%, respectively, at the intervention laboratories and 14% in the
control laboratories for the second observation on average. Above laboratory costs account for 6% for the interven-
tion and 7% for the control laboratories on average.
3.3. Unit costs
Bottom-up and top-down laboratory unit costs for Xpert MTB/RIF and microscopy are displayed in Tables II
and III, respectively. For Xpert MTB/RIF, the mean bottom-up cost per test processed was $US16.9 (standard
deviation (SD), $US6.1) in comparison with the mean top-down cost of $US33.5 (SD, $US32.0). The mean
bottom-up unit costs were the same for observation 1 $US14.6 (SD, $US2.0) and 2 $US14.6 (SD, $US1.8)
(in intervention laboratories), whereas the top-down ﬁrst observation unit cost was $US28.4 (SD, $US28.0)
(in intervention laboratories) and the second observation measured a $US19.7 (SD, $US3.5) top-down unit
Table II. Unit costs Xpert MTB/RIF: top-down and bottom-up costs per test processed by input type, study arm and
observation ($US2013)
Start-up stages of
implementation
(~3 months of
implementationa)
Early stages of
implementation (~3–6
months of
implementationa)
Medium term stages of
implementation
(~12 months of
implementationa)
Time period Control (observation 2)
Intervention
(observation 1)
Intervention
(observation 2)
Top down-method
n = 5 n = 10 n = 9
Mean Range Mean Range Mean Range
Overheads $0.3 ($0.1; $0.6) $3.6 ($0.2; $29.4) $0.7 ($0.2; $1.7)
Transport $0.5 ($0.1; $1.0) $0.8 ($0.1; $2.9) $0.9 ($0.1; $2.9)
Building space $0.3 ($0.1; $1.2) $1.2 ($0.2; $6.4) $0.7 ($0.2; $2.1)
Equipment $35.2 ($0.6; $76.9) $1.3 ($1.0; $1.7) $1.6 ($0.9; $3.4)
Staff $10.0 ($2.2; $20.5) $2.7 ($0.5; $13.5) $1.5 ($0.1; $2.3)
Reagents and chemicals $10.9 ($9.8; $13.8) $15.3 ($10.3; $39.7) $12.5 ($9.7; $17.4)
Calibration $1.9 ($0.4; $4.1) $0.1 ($0.1; $0.7) $0.1 ($0.1; $0.1)
Training Xpert MTB/RIF speciﬁc $5.8 ($1.1; $14.1) $0.5 ($0.2; $2.1) $0.2 ($0.2; $0.5)
Consumables $0.3 ($0.1; $0.4) $1.5 ($0.0; $12.4) $0.3 ($0.0; $1.3)
Above service-level costs Xpert MTB/RIF $3.2 ($0.1; $11.0) $1.4 ($0.7; $3.6) $1.2 ($0.7; $3.1)
Mean unit cost for each Xpert MTB/RIF observation $68.4 (SD, $45.5) $28.4 (SD, $28.0) $19.7 (SD, $3.5)
Mean top down unit cost for Xpert MTB/RIF $33.5 (SD, $32.0)
Bottom-up method n = 5 n = 10 n = 6
Mean Range Mean Range Mean Range
Overheads $0.3 ($0.0; $1.0) $0.4 ($0.1; $0.9) $0.3 ($0.1; $0.6)
Transport $0.4 ($0.1; $1.0) $0.8 ($0.1; $2.9) $1.1 ($0.1; $2.9)
Building space $0.2 ($0.1; $0.5) $0.2 ($0.0; $0.4) $0.2 ($0.0; $0.8)
Equipment $1.6 ($0.2; $3.3) $0.5 ($0.0; $0.9) $0.8 ($0.3; $1.6)
Staff $1.0 ($0.3; $1.7) $0.9 ($0.1; $4.1) $0.7 ($0.1; $1.4)
Reagents and chemicals $9.7 ($9.7; $9.7) $9.7 ($9.7; $9.7) $9.7 ($9.7; $9.7)
Calibration $1.9 ($0.4; $4.1) $0.1 ($0.1; $0.7) $0.1 ($0.1; $0.1)
Training Xpert MTB/RIF speciﬁc $5.8 ($1.1; $14.1) $0.5 ($0.2; $2.1) $0.2 ($0.2; $0.3)
Consumables $0.2 ($0.1; $0.3) $0.1 ($0.0; $0.3) $0.1 ($0.0; $0.4)
Above service-level costs Xpert MTB/RIF $3.2 ($0.1; $11.0) $1.4 ($0.7; $3.6) $1.4 ($0.7; $3.1)
Mean unit cost for each Xpert MTB/RIF observation $24.3 (SD, $9.2) $14.6 (SD, $2.0) $14.6 (SD, $1.8)
Mean bottom-up unit cost for Xpert MTB/RIF $16.9 (SD, $6.1)
aAfter the last laboratory implemented Xpert MTB/RIF.
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cost. During the start-up stages of implementation, the mean bottom-up unit cost of Xpert MTB/RIF in control sites
was $US24.3 (SD, $US9.2) per test compared with a mean top-down measurement of $US68.4 (SD, $US45.5).
A paired t-test was performed to determine if the two methods (top-down and bottom-up) produced statis-
tically different results. There were a total of 21 observations with complete data for top-down and bottom-
up unit costs (n=21), and these were used in the paired t-test (Table SVI). A 95% conﬁdence interval about
the mean showed a signiﬁcant difference (0 did not fall in the range 5.36 and 31.88, leading us to reject the null
hypothesis that there is no difference between the two observation means). The mean (mean=18.62;
SD=29.12; n=21) was signiﬁcantly greater than zero, and the two-tail p=0.008 provides evidence that the
methods are notably different.
Table IV presents the costs estimated at the reference laboratory. The mean bottom-up and top-down costs
for each of the tests, respectively, were: microscopy $US3.6 and $US8.2; MTBDRplus $US20.3 and $US30.6;
MGIT culture $US12.9 and $US16.1; and drug susceptibility testing for streptomycin, isoniazid, rifampin and
ethambutol (DST MGIT SIRE) $US25.1 and $US53.7. These unit costs all include above laboratory costs.
Table SIV presents our estimates of incremental costs using two methods. We estimate an average incremental
cost of $US17.7 (top-down) and $US14.7 (bottom-up) for Xpert MTB/RIF. We present the ordinary least
squares regression analysis in Figure 2. We ﬁnd that scale, and by this we mean an increase in the number
of specimens requiring processing and those being processed, is a strong determinant of both bottom-up and
top-down costs with a correlation coefﬁcient of 0.66 and 0.79, respectively, (p<0.001).
Table III. Unit costs microscopy: top-down and bottom-up costs per test processed by input type, study arm and
observation ($US2013)
Control Intervention
Time period Observation 1 Observation 2 Observation 1 Observation 2
Top-down inputs
n = 9 n = 9 n = 9 n = 9
Mean Range Mean Range Mean Range Mean Range
Overheads $0.6 ($0.1; $1.3) $0.6 ($0.1; $1.3) $1.2 ($0.3; $2.8) $1.2 ($0.3; $2.8)
Transport $0.7 ($0.1; $2.1) $0.7 ($0.1; $2.1) $0.9 ($0.1; $2.9) $0.9 ($0.1; $2.9)
Building space $0.6 ($0.0; $1.5) $0.8 ($0.1; $1.5) $1.1 ($0.2; $4.4) $1.0 ($0.2; $4.4)
Equipment $0.3 ($0.1; $0.8) $0.3 ($0.0; $0.8) $0.7 ($0.2; $1.4) $0.7 ($0.2; $1.4)
Staff $1.1 ($0.4; $1.9) $1.1 ($0.4; $1.7) $1.7 ($0.5; $3.2) $1.6 ($0.3; $3.1)
Reagents and chemicals $1.0 ($0.1; $4.2) $1.0 ($0.1; $4.2) $2.6 ($0.3; $7.8) $2.5 ($0.1; $7.8)
Consumables $0.3 ($0.1; $0.4) $0.3 ($0.1; $0.9) $0.3 ($0.0; $1.3) $0.3 ($0.0; $1.3)
Above service-level costs
microscopy
$1.9 ($0.7; $4.0) $1.8 ($0.6; $3.8) $2.1 ($0.4; $3.4) $2.1 ($0.4; $3.3)
Mean unit cost for each microscopy
observation $6.4 (SD, $2.0) $6.8 (SD, $1.9) $10.6 (SD, $3.9) $10.4 (SD, $4.0)
Mean top down unit cost for
microscopy $8.5 (SD, $3.6)
Bottom-up inputs n = 9 n = 5 n = 8 n = 6
Mean Range Mean Range Mean Range Mean Range
Overheads $0.2 ($0.0; $0.5) $0.1 ($0.0; $0.3) $0.7 ($0.0; $1.9) $0.5 ($0.0; $1.9)
Transport $0.7 ($0.1; $2.1) $0.9 ($0.1; $2.1) $0.9 ($0.1; $2.9) $1.1 ($0.1; $2.9)
Building space $0.6 ($0.0; $3.6) $0.4 ($0.2; $0.6) $0.8 ($0.1; $4.5) $0.9 ($0.0; $4.5)
Equipment $0.3 ($0.1; $0.6) $0.1 ($0.1; $0.3) $0.3 ($0.1; $0.5) $0.2 ($0.1; $0.4)
Staff $0.4 ($0.1; $1.2) $0.3 ($0.2; $0.5) $1.1 ($0.1; $4.4) $0.6 ($0.2; $1.3)
Reagents and chemicals $1.7 ($0.4; $5.0) $1.0 ($0.2; $1.6) $0.5 ($0.1; $1.2) $0.8 ($0.1; $2.9)
Consumables $0.4 ($0.2; $0.9) $0.5 ($0.1; $0.9) $0.4 ($0.2; $0.8) $0.3 ($0.1; $0.7)
Above service-level costs
microscopy
$1.9 ($0.7; $4.0) $2.2 ($1.5; $3.8) $2.0 ($0.4; $3.4) $2.2 ($0.4; $3.3)
Mean unit cost for each microscopy
observation $6.2 (SD, $1.7) $5.5 (SD, $1.9) $6.6 (SD, $3.5) $6.7 (SD, $3.5)
Mean bottom up unit cost for
microscopy $6.3 (SD, $2.8)
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4. DISCUSSION
Using a mixed methods approach to costing, the XTEND pragmatic trial enabled us to assess and understand
the costs of rolling out Xpert MTB/RIF under routine ‘real-world’ conditions in South Africa (Churchyard,
2011). The difference between paired bottom-up and top-down unit costs for the laboratories were statistically
signiﬁcant. Our ﬁndings using the bottom-up approach are broadly in line with previous trial-based estimates
conducted using a primarily bottom-up method. Before the 40% price reduction in Xpert MTB/RIF cartridge
costs in 2012, Vassall et al. (2011a, 2011b) estimated the cost of Xpert MTB/RIF processing through measured
observation to be $US25.9 per test in South Africa. Including recent cartridge price reductions, this unit cost
(equivalent to $US19.0 when the price difference is subtracted) is slightly higher than the bottom-up cost we
calculated of $US16.9 using the bottom-up method in a routine setting and suggests that the bottom-up
methods used to cost tests during demonstration and clinical trial sites were somewhat robust to changes in
‘real-world’ implementation in South Africa.
However, our top-down costs differ from previous estimates. Although some of this difference may reﬂect
some inaccuracy in allocating resources, given that most of the laboratories were performing a limited range of
activities, the substantial difference in our top-down and bottom-up unit cost estimates also suggests a ‘real-world’
efﬁciency gap. The fact that this difference may be due to efﬁciency rather than measurement error is reﬂected in
Figure 2. Bottom-up and top-down unit costs for Xpert MTB/RIF for intervention laboratories observations 1 (blue) and 2 (orange), and
control laboratories (green) ($US2013) versus annual number of tests processed
Table IV. Top-down and bottom-up unit costs for reference laboratory tests by input type, study arm and observation
($US2013)
MTBDRplus
Fluorescence smear
microscopy
MGIT
Culture
DST MGIT
SIRE
Laboratory name Lab 21
Annual number of tests (for ﬁnancial year 2012/2013) 18 394 73 115 126 936 3914
Unit cost per specimen processed (bottom up) $US with above
service-level costs
$20.3 $3.6 $12.9 $25.1
Unit cost per specimen processed (top down) $US with above
service-level costs
$30.6 $8.2 $16.1 $53.7
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the fact that the top-down costs of Xpert MTB/RIF using the same measurement approach reduced substantially
over time during roll-out, from $US28.4 to $US19.7 in the intervention sites across the two observations, suggest-
ing improvements in the utilisation of ﬁxed resources during scale-up. Our results on the relationship between cost
and scale support this ﬁnding. Menzies et al. (2012a, 2012b) argue that an inverse relationship between volume
and cost may be attributed to economies of scale as well as experience of those processing. The process study
(Supporting Information and Table SV), using observation and discussion undertaken with laboratory staff, sug-
gests that during roll-out, processes and practices changed suggesting ‘learning by doing’ and poorly performing
sites closed down. This learning process relates to the adaptation of the new technology within the local setting
(Gilson and Schneider, 2010). It is, however, important to note that during the time that this study took place, there
were substantial resource constraints on the laboratory system in South Africa, which had bearing on the closure of
less efﬁcient and lower workload settings (Treatment action campaign, 2014; Health Systems Trust, 2012). Inter-
estingly, we ﬁnd economies of scale when we use both bottom-up and top-down costing methods. This suggests
that both resource under utilisation and the efﬁciency of processes become more efﬁcient as volumes increase.
Our analysis of incremental costs suggests that the Xpert MTB/RIF did not place any substantial incremental
burden on the ﬁxed capacity of the South African laboratory system (NHLS) (Vassall et al., 2011a; Vassall
et al., 2011b). Our method to assess incremental cost is simple but is complemented by our process evaluation,
which ﬁnds no increase was required in the total levels of building and human resources during the period of roll-
out. We found that, although the focus of effort shifted in intervention laboratories, overall levels of stafﬁng
remained the same as for microscopy and that any increased infrastructure requirements were absorbed with longer
opening hours.
It is unlikely that the speciﬁc ﬁndings above are generalizable or can be applied across settings and different new
technology types. In our case, our measurement of incremental costs, due to the excess capacity in ﬁxed costs and
the scale effect, did not substantially impact our previous conclusions on cost-effectiveness using bottom-up
measures at a smaller scale. Similar studies examining costs of HIV prevention and/or treatment have shown similar
patterns of cost reductions over time and by scale (Lépine et al., 2015; Tagar et al., 2014; Menzies et al., 2012b).
However, South Africa has a well-developed laboratory system, and other technologies have markedly different
resource proﬁles. Improvements over time in efﬁciency will also be highly dependent on programme and site
management and the volumes of tests at each site required to ensure high coverage. Therefore, analysts should
not presume that in all cases, initial bottom-up costs are accurate predictors of unit costs at scale when estimating
cost-effectiveness.
Our study also highlights that care needs to be taken regarding when to measure costs. Total costs ﬂuctuate
according to seasonal trends in TB rates and testing practices (Koh et al., 2013). Some of the ﬂuctuation was
also caused by stock-out of laboratory supplies during the roll-out process. Xpert MTB/RIF cartridge stock-
outs occurred in July, September, October 2012 and February 2013 because of insufﬁcient supply from the
stockists (Molapo, 2013). Laboratories often compensated for this by borrowing stock from other laboratories.
Our ﬁndings earlier are subject to certain limitations. The percentage of laboratories that was not observed
for all the planned observations may have biased the ﬁndings in terms of measures of efﬁciency. Our sample
size, although large for a costing study, was too small for performing more sophisticated econometrics to
analyse cost drivers. Although it allowed for the scope of methods used, including robust economies of scale
and statistical analysis of costs using the two different methods. Care should be taken when generalising our
ﬁndings to other settings (as described earlier). Our ﬁndings in this setting are highly dependent on the proportion
of ﬁxed costs and the extent and characteristics of inefﬁciency within the South African laboratory systems. Top-
down and bottom-up methods may therefore align better in other settings. More studies are needed to examine this
research gap, and we recommend further testing in other areas prior to the full acceptance of the use of these dual
methodologies.
Current guidance on how to incorporate efﬁciency into cost estimation is often broad, suggesting assump-
tions (such as applying 80% capacity usage) acknowledging that in practice this is likely to vary by healthcare
setting (Drummond et al., 1997). New tools, such as the OneHealth Tool (which is publically available for
download), are being developed that allow the improved estimation of capacity across a health system (Futures
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Institute, 2014) but as yet cannot be applied to speciﬁc new technologies. Given the range of costing estimates
found using different approaches, we recommend that when making country-speciﬁc estimates of incremental
costs for cost-effectiveness or budget impact purposes to use the dual approach suggested here. As this may not
always be feasible, at the very least, analysts should more carefully present, which costs were measured using
the different approaches.
Bottom-up costing methods are more feasible where procedures are frequently performed and/or detailed
resource use data are available, for instance, with patient-level resource use (Mercier and Naro, 2014; Wordsworth
et al., 2005). They can pose a logistical challenge, however, where the procedures are performed infrequently and
observation may also bias results by impacting the behaviour of those conducting the procedure. In comparison,
the top-downmethod included here required considerable engagement and participation by the study sites in terms
of access to expenditure data and willingness to ﬁll in data collection instruments such as timesheets (Wordsworth
et al., 2005). This level of engagement may only be feasible where funding is sufﬁcient and the time frame allows
for agreements to be made early on during a costing study. A particular issue is that expenditure data for top-down
costing is in centralised systems, which may not be accessible at study sites and can take considerable time and
effort to access and apportion. Hendriks et al. (2014) provide an illustrative guide to collecting top-down cost data
when expenditure data are difﬁcult to collect. Nevertheless, once that engagement is established and access
provided, we found that using both methods was not substantially more time consuming per site.
Moreover, the two costing methods provided complementary insight for NHLS managers in South Africa
and have several policy and practice implications beyond economic evaluation, which is contrary to the inter-
pretation of using both practices by Mercier and Naro (2014) who found the lack of agreement between the two
methods disagreeable. Commonly, budget setting and negotiations in South Africa use a method of bottom-up
ingredients costing. But in practice, real expenditure (as captured in top-down methods) exceeds these funds,
creating substantial budgetary pressure. These two measurements of costs allow for a more informed discussion
of the budget during and post-scale-up. Such discussions should also include an assessment of feasible efﬁ-
ciency improvements. Moreover, the comparison between these costs from speciﬁc sites allow the NHLS to
identify areas and practices that require further process and efﬁciency improvement in speciﬁc sites during
the ﬁnal stages of roll-out.
Finally, the sample size of our study was considerably larger than is common in costing studies of new tech-
nologies at early stages of global roll-out generally, which is rarely feasible given the scarce funding for such
studies. However, this sample size enabled some assessment of economies of scale that may be useful in
promoting discussion on Xpert MTB/RIF placement in other settings. In addition, it provides information for
policy makers and planners to provide adequate budgets for settings with low-density populations (as is com-
mon in many LMIC settings). More analysis is required to better understand the trade-off between ensuring
thorough site-level data collection versus increasing sample size.
5. CONCLUSION
This study provides an example of a pragmatic, but comprehensive, approach to measuring the costs of new tech-
nologies during their roll-out, which can be incorporated into economic evaluations and budget impact estimates in
LMIC settings. The clarity gained from being explicit about bottom-up and top-down approaches, together with a
moderate sample size, process study, observation and discussion with laboratory staff, can support policy makers
and planners to make more accurate estimates of the resource requirements of the scale-up of new technologies in
settings where resources are extremely scarce.
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